Context Pulmonary carcinoids (PC) belong to neuroendocrine tumors that often overexpress somatostatin receptors (SSTR). This overexpression provides a molecular basis for tumor imaging and treatment with somatostatin analogs. Objective To evaluate SSTR1–5 distribution in a large set of PC tumors and to investigate whether the expression is associated with clinicopathological and outcome data. Design, setting and patients This retrospective study was conducted at Helsinki University Hospital and University of Helsinki. It included 178 PC tumors coupled with patients’ clinical data retrieved through Finnish biobanks. After histological re-classification, tissue specimens were processed into next-generation tissue microarray format and stained immunohistochemically with novel monoclonal SSTR1-5 antibodies. Main outcome measure SSTR1-5 expression in PC tumors. Results Expression of SSTR1–5 was detected in 52%, 75%, 56%, 16%, and 32% of the tumors, respectively. Membrane-bound staining was observed for all receptors. SSTR2 negativity and SSTR4 positivity was associated with lymph node involvement at the time of surgery (P=0.014 and P=0.017, respectively) and with distant metastasis (P=0.027 and P=0.015, respectively). SSTR3 and SSTR4 expression was associated with increased risk of shorter survival (P=0.046, HR 4.703, 95% CI 1.027-21.533 and P=0.013, HR 6.64, 95% CI 1.48-29.64, respectively) while expression of SSTR1 and SSTR2 was associated with improved outcome (P=0.021, HR 0.167, 95% CI 0.037–0.765 and P=0.022, HR 0.08, 95% CI 0.01-0.70, respectively). Conclusion SSTR1–5 expression is observed in pulmonary carcinoids. As SSTR expression is associated with the tumor’s metastatic potential and patient outcome, these receptors may offer the possibility for individualized prognosis estimation.